Citations

Clear

9383 citation(s) found for "Thomas, PS".

Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer
Rami, Avina , Zhong, Caiwei , Muniz, Miguel, Khorasanchi, Adam , Fein, Daniel , Stoltenberg, Hailey, Gopalakrishan, Dharmesh, Yang, Yuanquan , Ng, Thomas S.C. , Gafita, Andrei , Jacene, Heather A. , Ravi, Praful , Muniz, Miguel , Khorasanchi, Adam , Fein, Daniel , Ng, Thomas S C , Childs, Daniel S , Xie, Wanling , Gallagher, John F. , Mohammadi, Sedra, Voter, Andrew F. , Childs, Daniel S.

Mayo Clinic

Cancers | June 12, 2025 | Volume: 17 | Issue: 12 | Pages: 1960

10.3390/cancers17121960 | PMID 40563610 Get It

Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [177Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and outcomes with LuPSMA in a multi-institutional cohort of consecutive patients with mCRPC treated with LuPSMA. The primary outcomes were PSA-50 rate, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Statistical models were adjusted for age, number of prior therapies, sites of metastases, and baseline PSA. A total of 654 patients were included; 593 (91%) were White, 45 (7%) were Black and 16 (2%) were another non-Black minority (NBM). There were no statistically significant differences in PSA-50 rates, PSA-PFS and OS between the groups. Black and White patients treated with LuPSMA had similar clinical outcomes; efforts are needed to ensure Black and NBM patients have equal access to life prolonging therapies to narrow disparities in outcomes.
Reply to “A Simple Path Forward to Reducing Excessive Radiation Doses for CT”
Wells, Jered R. , Christianson, Olav, Gingold, Eric L. , Jacobs, Jurgen, Boedeker, Kirsten , Ramírez-Giraldo, Juan Carlos , Yu, Lifeng , Samei, Ehsan , Gress, Dustin A. , Yu, Lifeng , McNitt‐Gray, Michael F.

Mayo Clinic

American Journal of Roentgenology | June 11, 2025 | Volume: 226 | Issue: 1 | Pages: No page available

10.2214/ajr.25.33253 | PMID 40499023 Get It

Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Loo, Billy W. , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Dowell, Jonathan E. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Lovly, Christine Marie , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 255-269

10.6004/jnccn.2025.0027 | PMID 40499586 Get It

Thymomas and thymic carcinomas are rare mediastinal tumors that originate in the thymus. Patients with thymoma may experience symptoms associated with autoimmune paraneoplastic diseases (such as myasthenia gravis), which typically do not occur in patients with thymic carcinoma. The NCCN Guidelines for Thymomas and Thymic Carcinomas provide guidance for the diagnosis, treatment, and surveillance of patients with thymoma and thymic carcinoma. Involvement of a multidisciplinary team with experience treating thymomas and thymic carcinomas is highly recommended.
Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Kang, Bianca Y. , Cohen, Joel L. , Geronemus, Roy G. , Kilmer, Suzanne L. , Ross, E. Victor , Tanzi, Elizabeth L., Waibel, Jill , Alam, Murad, Alexiades, Macrene , Arndt, Kenneth A., Avram, Mathew M., Biesman, Brian S. , Bloom, Jason D. , Burns, A. Jay, DiGiorgio, Catherine M., Dover, Jeffrey S. , Fathizadeh, Sam, Esteves, Sara C., Goldberg, Gerald N., Hoss, Elika, Ibrahimi, Omar A. , Jalian, H. Ray, Kelly, Kristen M. , Munavalli, Girish Gilly , Pozner, Jason N. , Robb, Christopher W. , Saedi, Nazanin, Shumaker, Peter R. , Stankiewicz, Kelly, Wanner, Molly, Wu, Douglas C. , Wulkan, Adam J., Ortiz, Arisa , Ross, Edward Victor , Alexiades, Macrene , Chan, Henry H L , Fathizadeh, Sam , Kelly, Kristen M , Manuskiatti, Woraphong , Munavalli, Girish S , Robb, Chris W , Wong, Brian J. F. , Bhatia, Ashish C. , ESTEVES, SARA C., Gold, Michael H , Hædersdal, Merete , Marks, Lisa , Rossi, Anthony M.

Mayo Clinic

Lasers in Surgery and Medicine | June 11, 2025 | Volume: 57 | Issue: 6 | Pages: 477-489

10.1002/lsm.70035 | PMID 40495549 Get It

ABSTRACTObjectivesTo achieve consensus among expert laser surgeons on standards for the prevention and management of adverse events from fully ablative laser resurfacing of the face.Materials and MethodsDelphi study with two rounds of ratings and revisions until consensus was achieved. The draft set of statements was developed by a steering committee based on expert clinical experience. This was followed by two rounds of rating and revisions completed by an expert panel, then a virtual consensus meeting. In both rounds, respondents rated the draft statements on a 9‐point Likert scale (1 = strongly disagree; 9 = strongly agree) and optionally provided comments. The consensus meeting was supplemented by the results of a systematic review of the literature (from 2000 to 2023).ResultsTwo rounds of Delphi survey were completed by 34 participants across four countries. Represented specialties were dermatology, facial plastic surgery, plastic surgery, and oculoplastic surgery. The initial 105 statements from round 1 expanded to 112 in round 2, with 96 statements achieving consensus. These included possible adverse events (11 statements); absolute and relative contraindications to treatment (5 statements); preoperative care and antimicrobial prophylaxis precautions (16 statements); intraoperative precautions (17 statements); postoperative care (21 statements); monitoring for and management of infection (16 statements); management of pigmentation changes (6 statements); and management of scarring and incipient scarring (4 statements).ConclusionAn international consensus statement was developed for the prevention and management of complications associated with fully ablative laser resurfacing of the face. While expert practices vary, key factors for optimizing outcomes include careful patient selection, counseling, and meticulous pre‐ and postoperative care. Further research will improve our understanding of this treatment technique.
Conditioned Generative Modeling of Molecular Glues: A Realistic AI Approach for Synthesizable Drug-like Molecules
Islam, Naeyma N., Caulfield, Thomas R. , Caulfield, Thomas R

Mayo Clinic

Biomolecules | June 10, 2025 | Volume: 15 | Issue: 6 | Pages: 849

10.3390/biom15060849 | PMID 40563489 Get It

Alzheimer’s disease (AD) is marked by the pathological accumulation of amyloid beta-42 (Aβ42), contributing to synaptic dysfunction and neurodegeneration. While extracellular amyloid plaques are well-studied, increasing evidence highlights intracellular Aβ42 as an early and toxic driver of disease progression. In this study, we present a novel, Generative AI–based drug design approach to promote targeted degradation of Aβ42 via the ubiquitin–proteasome system (UPS), using E3 ligase–directed molecular glues. We systematically evaluated the ternary complex formation potential of Aβ42 with three E3 ligases (CRBN, VHL, and MDM2) through structure-based modeling, ADMET screening, and docking. We then developed a Ligase-Conditioned Junction Tree Variational Autoencoder (LC-JT-VAE) to generate ligase-specific small molecules, incorporating protein sequence embeddings and torsional angle-aware molecular graphs. Our results demonstrate that this generative model can produce chemically valid, novel, and target-specific molecular glues capable of facilitating Aβ42 degradation. This integrated approach offers a promising framework for designing UPS-targeted therapies for neurodegenerative diseases.
Assessing Renal Function Recovery Following Treatment for Post-Robot-Assisted Partial Nephrectomy Renal Artery Pseudoaneurysm
Kahn, Amanda E. , Geldmaker, Laura , Qosja, Neda, Haehn, Daniela A. , Fuqua, Taylor F., Tiwari, Vartika, Hochwald, Alex, Thomas, Colleen S. , Thiel, David D. , Kahn, Amanda , Fuqua, Taylor F.

Mayo Clinic

Journal of Endourology | June 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/end.2025.0046 | PMID 40491414 Get It

Hurting More Than Helping? Decompressive Craniectomy in Patients With Symptomatic Intracerebral Hemorrhage After Mechanical Thrombectomy in Acute Ischemic Stroke: Insights From Stroke Thrombectomy and Aneurysm Registry
Pressman, Elliot , Vakharia, Kunal , Guerrero, Waldo R. , Maier, Ilko , Raai, Ansaar, Jabbour, Pascal , Kim, Joon-Tae , Grossberg, Jonathan A , Wolfe, Stacey Q , Stark, Robert M., Psychogios, Marios‐Nikos , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Moss, Mark, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Mokin, Maxim, STAR, on behalf of, Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Ogilvy, Christopher S , Sowlat, Mohammad‐Mahdi , Schimmel, Samantha J. , Jabbour, Pascal , Alawieh, Ali , Stark, Robert M., Samaniego, Edgar A , Goyal, Nitin , Fiorella, David , Romano, Daniele G., Navía, Pedro , Cuellar, Hugo, Fragata, Isabel , Mascitelli, Justin R , Osbun, Joshua W , Limaye, Kaustubh , Matouk, Charles , Park, Min S. , Levitt, Michael R. , Gory, Benjamin , Grandhi, Ramesh , Paul, Alexandra R , Mokin, Maxim , STAR, on behalf of

Mayo Clinic

Neurosurgery | June 9, 2025 | Volume: 98 | Issue: 2 | Pages: 345-357

10.1227/neu.0000000000003563 | PMID 40488514 Get It

BACKGROUND AND OBJECTIVES: It remains unclear whether decompressive craniectomy (DC) is beneficial in patients who suffer symptomatic intracerebral hemorrhage (sICH) after acute ischemic stroke (AIS). We sought to study the effect of DC on functional outcomes in patients with sICH after AIS who underwent mechanical thrombectomy (MT). METHODS: Patients with AIS from anterior circulation large vessel occlusion who underwent MT and subsequently developed sICH were identified from the Stroke Thrombectomy and Aneurysm Registry database. The primary outcome was acceptable 90-day functional neurological outcome, defined as modified Rankin scale (mRS) 0-3. Multivariable logistic regression and propensity-score matching were used to identify and quantify risk factors. RESULTS: Of 464 patients identified with sICH after AIS after MT, 97 patients (20.9%) underwent DC. Patients who underwent DC were more likely to be female ( P < .001), younger ( P < .001), have a measured medical comorbidity, have higher baseline mRS ( P = .02), and have higher-grade hemorrhages ( P = .01). At 90 days, 14% of patients had the primary outcome of mRS 0-3 and 56% had died. The primary outcome was observed in 11 patients who underwent DC (11%) and 55 (15%) of those without DC (odds ratio [OR] 0.7, 95% CI 0.4-1.4, P = .40). DC did not affect mRS shift at 90 days ( P = .10) but was associated with lower mortality (OR 0.5, 95% CI 0.3-0.8, P = .01). Multivariable analysis demonstrated that DC decreased the odds of primary outcome (adjusted OR 0.2, 95% CI 0.02-0.9, P = .045), but did not affect mortality ( P = .94), mRS shift ( P = .50), or length of stay ( P = .90). Propensity-matched analysis similarly demonstrated that non-DC patients were more likely to achieve the primary outcome (24% vs 8%, P = .045). CONCLUSION: In patients with sICH after AIS after MT, those selected for DC had less favorable outcomes and similar rates of mortality at 90 days.
Diagnosis‐to‐Ablation Time to Predict the Recurrence of Atrial Fibrillation Following Catheter Ablation: A Systematic Review and Meta‐Analysis
Najeeb, Hala , Zaidi, Syeda Farwa, Moeed, Abdul, Yasmin, Farah , Asghar, Muhammad Sohaib , Ullah, Waqas, Asghar, Muhammad S , Alraies, M Chadi , Moeed, Abdul , Ullah, Waqas

Mayo Clinic

Clinical Cardiology | June 9, 2025 | Volume: 48 | Issue: 6 | Pages: No page available

10.1002/clc.70149 | PMID 40485638 Get It

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
Vannucchi, Alessandro M. , Mascarenhas, John , Bose, Prithviraj , Gale, Robert Peter , Harrison, Claire , Hehlmann, Rüdiger , Koschmieder, Steffen , Tefferi, Ayalew , Barbui, Tiziano , Vannucchi, Alessandro M , Mascarenhas, John , Gale, Robert P , Bose, Prithviraj , Koschmieder, Steffen , Marchetti, Monia , Álvarez‐Larrán, Alberto , Hehlmann, Rűdiger, Kiladjian, Jean‐Jacques , Mesa, Ruben A. , Passamonti, Francesco , Rambaldi, Alessandro

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6785954/v1 Get It

Abstract Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality-of-life. This 1–2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) taskforce developed a composite endpoint which allows multiple outcomes to be simultaneously measured. The panel used the Desirability-Of-Outcome-Ranking (DOOR) method to assign 25 outcomes into 4 quartiles based on a multi-dimensional desirability score and build a 5-layer composite outcome named Desirability-of-Myelofibrosis-Outcomes (DEMYO). Outcome operational definitions were tested by Delphi consensus and correlations with survival validated by a literature review. The outcomes assigned to the first two quartiles were negatively correlated with leukemia-free survival and survival. DEMYO comprehensively captures relevant MF clinical features and meaningful endpoints. Despite DEMYO requires validation based on available trial data, it is expected to improve the quality of Health Authority approvals for new drugs for MF.
Histidine decarboxylase inhibition attenuates cancer-associated muscle wasting
Dasgupta, Aneesha , Schmitt, R. , Kono, Tatsuyoshi , Lee, Chih‐Chun , Zoberi, Mark I. , Epstein, Savannah A. , Schneider, Jessica Z. , Hernández, Alejandro A. Avecilla , Grandgenett, Paul M. , Caffrey, Thomas C. , DiMaio, Dominick J. , Schmitt, Rebecca E , Hernandez, Alejandro , Hollingsworth, Michael A , Doles, Jason D , Grandgenett, Paul M , Hollingsworth, Michael A. , Doles, Jason D.

Mayo Clinic

Journal of Experimental Medicine | June 6, 2025 | Volume: 222 | Issue: 9 | Pages: No page available

10.1084/jem.20242239 | PMID 40600951 Get It

Cancer cachexia is a multifactorial syndrome involving muscle and fat wasting, inflammation, and metabolic dysfunction. Across cancer subtypes, pancreatic cancer has one of the highest cachexia incidence rates at ∼80%. Given the advanced age of most pancreatic cancer patients, we sought to query cancer-associated muscle wasting using an age-matched murine model. We found that histamine and histamine decarboxylase (HDC) activity were specifically elevated in the muscles of aged tumor-bearing mice. We further found that (1) wasting stimuli induced histamine production and enhanced HDC activity; (2) exogenous histamine was sufficient to induce atrophy-associated gene expression; (3) inhibition of HDC activity by α-fluoromethylhistidine (FMH) protected against atrophy; (4) treatment of tumor-bearing mice with FMH rescued muscle wasting; and (5) a calcineurin inhibitor was able to rescue histamine-associated increases in calcium/atrogene signaling. In summary, we present a novel metabolic pathway that has significant implications for the treatment of cachectic cancer patients.